Rahim Najia, Naqvi Syed Baqir Shyum, Alam Mehtab, Rasheed Abdur, Khalique Urooj Abdul
Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.
Institute of Pharmaceutical and Environmental Research, Dow University of Health Sciences, Karachi, Pakistan.
Pak J Pharm Sci. 2016 Mar;29(2):453-9.
The current study was aimed to judge bioequivalence between two formulations of cefadroxil capsules as guided by FDA guidelines. Another objective was to conduct pharmacokinetic evaluation in Pakistani population. A single-dose, randomized, cross-over pharmacokinetic study was conducted during the month of May'2013 to August'2013. Washout period was one week. Fourteen healthy male adult volunteers were enrolled in the study, however twelve completed the study. Cefadroxil plasma concentration was analyzed by using validated HPLC method. Protein precipitation was achieved by the addition of 6% tri chloro acetic acid in 1:1 ratio and detection was done at 260 nm. Retention time was 7.792 min and correlation coefficient (R2) was 0.9953 showing linearity of the method. Blood sampling was carried out at different time intervals after administration of either test (TEST 500 mg) or reference (REF® 500 mg) formulation. Pharmacokinetic parameters (AUC0→ ∞, AUC0→ t, Cmax, Tmax, t1/2 and kel) were calculated using Kinetica® PK/PD software. The geometric mean ratios and 90% confidence interval (CI) of these pharmacokinetic parameters for cefadroxil (test and reference) formulations were 0.986 (90.83-106.98%) for AUC0→ t; 0.967 (89.13-104.92%) for AUC0→ ∞ and 0.999 (91.06-109.69%) for Cmax. The differences between Tmax of both formulations were not found to be statistically significant (p-value was more than 0.05). The 90% CI of the test/reference AUC and Cmax ratio of cefadroxil were within the FDA recommended range for bioequivalence. Maximum plasma concentration Cmax was 12.5 μg/ml for test and 12.47 μg/ml for reference formulations. Average time to reach Cmax for test and reference formulation was 1.54 and 1.5 hrs. The two formulations of cefadroxil studied during the above study were verified bioequivalent. Maximum plasma concentration of cefadroxil was lower than those mentioned in some previous studies, while Tmax and half-life were near to values reported in literature.
本研究旨在按照美国食品药品监督管理局(FDA)的指导方针,判定头孢羟氨苄胶囊两种制剂之间的生物等效性。另一个目标是在巴基斯坦人群中进行药代动力学评估。2013年5月至2013年8月期间开展了一项单剂量、随机、交叉药代动力学研究。洗脱期为一周。14名健康成年男性志愿者参与了该研究,但12人完成了研究。采用经过验证的高效液相色谱法(HPLC)分析头孢羟氨苄的血浆浓度。通过按1:1比例加入6%三氯乙酸实现蛋白沉淀,并在260nm波长处进行检测。保留时间为7.792分钟,相关系数(R2)为0.9953,表明该方法具有线性关系。在给予受试制剂(TEST 500mg)或参比制剂(REF® 500mg)后,于不同时间间隔进行血样采集。使用Kinetica® PK/PD软件计算药代动力学参数(AUC0→∞、AUC0→t、Cmax、Tmax、t1/2和kel)。头孢羟氨苄(受试和参比)制剂这些药代动力学参数的几何平均比值和90%置信区间(CI)为:AUC0→t为0.986(90.83 - 106.98%);AUC0→∞为0.967(89.13 - 104.92%);Cmax为0.999(91.06 - 109.69%)。两种制剂的Tmax差异无统计学意义(p值大于0.05)。头孢羟氨苄受试/参比AUC和Cmax比值的90%CI在FDA推荐的生物等效性范围内。受试制剂的最大血浆浓度Cmax为12.5μg/ml,参比制剂为12.47μg/ml。受试和参比制剂达到Cmax的平均时间分别为1.54小时和1.5小时。上述研究中所研究的两种头孢羟氨苄制剂经证实具有生物等效性。头孢羟氨苄的最大血浆浓度低于一些先前研究中提及的浓度,而Tmax和半衰期接近文献报道的值。